{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:23:37Z","timestamp":1787315017828,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40258-026-01054-2","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:11:42Z","timestamp":1782929502000},"page":"801-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Price of National Pharmaceutical Pricing in the EU: A Proposal for \u201cCommon Procurement\u201d"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-266X","authenticated-orcid":false,"given":"Markus","family":"Frischhut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-2873","authenticated-orcid":false,"given":"Simona","family":"Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-1789","authenticated-orcid":false,"given":"Laura","family":"Magazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-5491","authenticated-orcid":false,"given":"Paolo","family":"Pertile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1054_CR1","unstructured":"European Union. Treaty on the Functioning of the European Union. Lisbon, 2016. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:02016E\/TXT-20250315. Accessed  18 May 2026."},{"key":"1054_CR2","unstructured":"Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions\u2014Pharmaceutical Strategy for Europe, 2020. https:\/\/health.ec.europa.eu\/medicinal-products\/pharmaceutical-strategy-europe_en. Accessed 18 May 2026."},{"key":"1054_CR3","unstructured":"Newton M, Stoddart K, Travaglio M, Troein P (2025) EFPIA patients W.A.I.T. indicator 2024 survey. https:\/\/www.iqvia.com\/library\/publications\/the-patients-wait-indicator-2025. Accessed 20 Feb 2026."},{"key":"1054_CR4","unstructured":"Draghi M. The future of European competitiveness. Part B | In-depth analysis and recommendations, 2024. https:\/\/commission.europa.eu\/topics\/strengthening-european-competitiveness\/eu-competitiveness-looking-ahead_en. Accessed 26 Feb 2026."},{"issue":"2","key":"1054_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14737167.2016.1223543","volume":"17","author":"S Vogler","year":"2017","unstructured":"Vogler S, Zimmermann N, Babar ZUD. Price comparison of high-cost originator medicines in European countries. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):221\u201330. https:\/\/doi.org\/10.1080\/14737167.2016.1223543.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"1054_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046917","volume":"11","author":"JMJ Daalen","year":"2021","unstructured":"Daalen JMJ, et al. Determinants of drug prices: a systematic review of comparison studies. BMJ Open. 2021;11(7):e046917. https:\/\/doi.org\/10.1136\/bmjopen-2020-046917.","journal-title":"BMJ Open"},{"issue":"3","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hec.931","volume":"14","author":"PM Danzon","year":"2005","unstructured":"Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs\u2014evidence from twenty-five major markets in the 1990s. Health Econ. 2005;14(3):269\u201392. https:\/\/doi.org\/10.1002\/hec.931.","journal-title":"Health Econ"},{"issue":"2","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1257\/mic.20210053","volume":"15","author":"L Maini","year":"2023","unstructured":"Maini L, Pammolli F. Reference pricing as a deterrent to entry: evidence from the European pharmaceutical market. Am Econ J Microecon. 2023;15(2):345\u201383. https:\/\/doi.org\/10.1257\/mic.20210053.","journal-title":"Am Econ J Microecon"},{"issue":"6","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/hec.1630","volume":"20","author":"B Garcia Mari\u00f1oso","year":"2011","unstructured":"Garcia Mari\u00f1oso B, Jelovac I, Olivella P. External referencing and pharmaceutical price negotiation. Health Econ. 2011;20(6):737\u201356. https:\/\/doi.org\/10.1002\/hec.1630.","journal-title":"Health Econ"},{"issue":"1","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-022-08866-7","volume":"22","author":"M B\u00fcssgen","year":"2022","unstructured":"B\u00fcssgen M, Stargardt T. Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades. BMC Health Serv Res. 2022;22(1):1\u201310. https:\/\/doi.org\/10.1186\/s12913-022-08866-7.","journal-title":"BMC Health Serv Res"},{"key":"1054_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj-2025-084839","volume":"391","author":"Z Kal\u00f3","year":"2025","unstructured":"Kal\u00f3 Z, Kruja K, Noone D, Vogler S, Docteur E. Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing. BMJ. 2025;391:1\u20134. https:\/\/doi.org\/10.1136\/bmj-2025-084839.","journal-title":"BMJ"},{"key":"1054_CR12","unstructured":"Vogler S. Access to information in markets for medicines in the WHO European Region. Oslo Medicines Initiative technical report. World Health Organization. Regional Office for Europe, 2022. https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289058322. Accessed 10 May 2026."},{"key":"1054_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100375","volume":"16","author":"K Perehudoff","year":"2022","unstructured":"Perehudoff K. European governments should align medicines pricing practices with global transparency norms and legal principles. Lancet Reg Health Eur. 2022;16:100375. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100375.","journal-title":"Lancet Reg Health Eur"},{"issue":"S1","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hec.4112","volume":"29","author":"S Gamba","year":"2022","unstructured":"Gamba S, Pertile P, Vogler S. The impact of managed entry agreements on pharmaceutical prices. Health Econ. 2022;29(S1):47\u201362. https:\/\/doi.org\/10.1002\/hec.4112.","journal-title":"Health Econ"},{"key":"1054_CR15","doi-asserted-by":"publisher","unstructured":"Barrenho E, Lopert R. Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets, OECD Health Working Papers No. 146, 2022. https:\/\/doi.org\/10.1787\/18152015.","DOI":"10.1787\/18152015"},{"key":"1054_CR16","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1017\/S1744133125100236","volume":"1\u201313","author":"T Kleinhout-Vliek","year":"2025","unstructured":"Kleinhout-Vliek T, Geiger S, Hagendijk R, Hilberg E, Martin P, Perehudoff K, et al. Constructing a single market for pharmaceuticals in the EU: what\u2019s the price? Health Econ Policy Law. 2025;1\u201313:2025. https:\/\/doi.org\/10.1017\/S1744133125100236.","journal-title":"Health Econ Policy Law"},{"key":"1054_CR17","unstructured":"European Observatory on Health Systems and Policies, Webb E, Richardson E, Vogler S, Panteli D. What are the implications of policies increasing transparency of prices paid for pharmaceuticals? A primer for understanding the policy perspective in light of the empirical evidence. World Health Organization. Regional Office for Europe. 2022. https:\/\/eurohealthobservatory.who.int\/publications\/i\/what-are-the-implications-of-policies-increasing-transparency-of-prices-paid-for-pharmaceuticals.Accessed 2 March 2026."},{"key":"1054_CR18","unstructured":"European Parliament Committee on the Environment, Public Health and Food Safety, REPORT on the shortage of medicines\u2014how to address an emerging problem, Report-A9-0142\/2020, 2020. https:\/\/www.europarl.europa.eu\/doceo\/document\/A-9-2020-0142_EN.html. Accessed 10 May 2026."},{"key":"1054_CR19","unstructured":"Council Conclusions on Common values and principles in European Union Health Systems, 2006. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A52006XG0622%2801%29. Accessed 18 May 2026."},{"key":"1054_CR20","unstructured":"Gamba S, Magazzini L, Pertile P. Improving access to medicines and promoting pharmaceutical innovation, 2023. https:\/\/www.europarl.europa.eu\/thinktank\/en\/document\/EPRS_STU(2023)753166. Accessed 2 March 2026."},{"key":"1054_CR21","unstructured":"Vogler S, Lepusch\u00fctz L, Schneider P, St\u00fchlinger V. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Directorate-General for Health and Food Safety Health systems, medical products and innovation, Luxembourg: Publications Office of the European Union. 2015. https:\/\/jasmin.goeg.at\/id\/eprint\/218\/2\/Study%20on%20enhanced%20cross-country%20coordination%20in%20the%20area%20of%20pharmaceutical%20product%20pricing.%20Final%20report.pdf. Accessed 2 March 2026."},{"key":"1054_CR22","unstructured":"World Health Organization Regional Office for Europe. European Programme of Work, 2020\u20132025. United action for better health. Copenhagen. 2021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/339209\/WHO-EURO-2021-1919-41670-56993-eng.pdf?sequence=1&isAllowed=y. Accessed 18 Feb 2026."},{"key":"1054_CR23","unstructured":"World Health Organization Regional Office for Europe. Second European Programme of Work, 2026\u20132030. United action for better health. Copenhagen. 2021. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/92dbfbc7-a354-438d-956e-dfd80a999487\/content. Accessed 18 Feb 2026."},{"issue":"10","key":"1054_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2471\/BLT.21.285761","volume":"99","author":"S Vogler","year":"2021","unstructured":"Vogler S, Haasis MA, van den Ham R, Humbert T, Garner S, Suleman F. European collaborations on medicine and vaccine procurement. Bull World Health Organ. 2021;99(10):715. https:\/\/doi.org\/10.2471\/BLT.21.285761.","journal-title":"Bull World Health Organ"},{"issue":"9","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.socscimed.2012.05.044","volume":"75","author":"M Huff-Rousselle","year":"2025","unstructured":"Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions? Soc Sci Med. 2025;75(9):1572\u201380. https:\/\/doi.org\/10.1016\/j.socscimed.2012.05.044.","journal-title":"Soc Sci Med"},{"key":"1054_CR26","unstructured":"World Health Organization. Cross-country collaborations to improve access to medicines and vaccines in the WHO European Region. 2020. Licence: CC BY-NC-SA 3.0 IGO. https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289055031."},{"key":"1054_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.17104\/0044-2348-2021-1-89","volume":"81","author":"AV Bogdandy","year":"2021","unstructured":"Bogdandy AV, Villarreal PA. The role of international law in vaccinating against COVID-19: appraising the COVAX Initiative 2021. Heidelb J Int Law. 2021;81:89\u2013116. https:\/\/doi.org\/10.17104\/0044-2348-2021-1-89.","journal-title":"Heidelb J Int Law"},{"issue":"4","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1017\/err.2020.91","volume":"11","author":"E McEvoy","year":"2020","unstructured":"McEvoy E, Ferri D. The role of the joint procurement agreement during the COVID-19 pandemic: assessing its usefulness and discussing its potential to support a European health union. Eur J Risk Regul. 2020;11(4):851\u201363. https:\/\/doi.org\/10.1017\/err.2020.91.","journal-title":"Eur J Risk Regul"},{"key":"1054_CR29","unstructured":"European Commission. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions: The European Health Union: acting together for people's health, 2024. https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_24_2523. Accessed 18 May 2026."},{"key":"1054_CR30","unstructured":"European Parliament legislative resolution of 10 April 2024 on the proposal for a regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394\/2007 and Regulation (EU) No 536\/2014 and repealing Regulation (EC) No 726\/2004, Regulation (EC) No 141\/2000 and Regulation (EC) No 1901\/2006. https:\/\/oeil.secure.europarl.europa.eu\/oeil\/popups\/ficheprocedure.do?reference=2023\/0131(COD)&l=en. Accessed 18 May 2026."},{"key":"1054_CR31","unstructured":"European Commission. Proposal for a Regulation of the European Parliament and of the Council laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024\/795. COM(2025) 102 final, 2025. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex:52025PC0102. Accessed 18 May 2026."},{"issue":"1","key":"1054_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1017\/S1744133116000219","volume":"12","author":"N Azzopardi-Muscat","year":"2017","unstructured":"Azzopardi-Muscat N, Schroder-B\u00e4ck P, Brand H. The European Union Joint Procurement Agreement for cross-border health threats: what is the potential for this new mechanism of health system collaboration? Health Econ Policy Law. 2017;12(1):43\u201359. https:\/\/doi.org\/10.1017\/S1744133116000219.","journal-title":"Health Econ Policy Law"},{"key":"1054_CR33","unstructured":"Docteur E. Towards a new vision for shared responsibility in pharmaceutical pricing, coverage and reimbursement. Policy approaches building on principles of solidarity, transparency and sustainability. Oslo Medicines Initiative technical report. Copenhagen: WHO Regional Office for Europe, 2022. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"2","key":"1054_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131\u20139. https:\/\/doi.org\/10.1016\/j.jval.2017.12.007.","journal-title":"Value Health"},{"key":"1054_CR35","unstructured":"Regulation (EU) 2021\/2282 of the European Parliament and of the Council. 2021. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:32021R2282. Accessed 7 May 2026."},{"issue":"3","key":"1054_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/hec.3021","volume":"24","author":"P Danzon","year":"2015","unstructured":"Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Policy. 2015;24(3):294\u2013301. https:\/\/doi.org\/10.1002\/hec.3021.","journal-title":"Health Policy"},{"key":"1054_CR37","unstructured":"Regulation (EU, Euratom) 2024\/2509 of the European Parliament and of the Council. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:32024R2509. Accessed 18 May 2026."},{"key":"1054_CR38","unstructured":"Directive 2014\/24\/EU of the European Parliament and of the Council. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:32014L0024. Accessed 10 May 2026."},{"key":"1054_CR39","unstructured":"European Union. Treaty on European Union. Lisbon, 2007. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:02016M\/TXT-20250315. Accessed 18 May 2026."},{"key":"1054_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101589","volume":"61","author":"M Frischhut","year":"2026","unstructured":"Frischhut M, Prainsack B, Hervey TK, de Ruijter A, Sokol T, Guldemond N, et al. 20 Years of EU health values (2006\u20132026): four proposals for the future. Lancet Reg Health Eur. 2026;61:101589. https:\/\/doi.org\/10.1016\/j.lanepe.2026.101589.","journal-title":"Lancet Reg Health Eur"},{"key":"1054_CR41","unstructured":"Council Decision (EU) 2015\/1601 of 22 September 2015, no longer in force. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:32015D1601. Accessed 7 May 2026."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01054-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:34:54Z","timestamp":1787312094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-026-01054-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01054-2","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed equally.","order":8,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}